LENSAR, Inc.

NASDAQ:LNSR

Medical - Devices

Healthcare
$4.85 -8.15%

-$0.51 today

Market cap
$59.63M
Beta
0.87
P/E (TTM)
2.4
EPS (TTM)
$2.42
52W Low $5.06High $13.47

Volume 0.06M

Average 0.09M

LNSR Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

LENSAR, Inc.NASDAQ: LNSR

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $1.13M rose 5.3% year over year, behind the +11.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.5% from the prior quarter. Over 3 fiscal years it compounded at +9.7% a year.

Context

  • Depreciation & amortization amounted to 7.7% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +5.3% toward the trailing-twelve-month pace of +11.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.13M-3.5% QoQ
Last fiscal yearDec 2025
$4.5M+14.5% YoY
LTMMar 2026
$4.56M+11.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.3%——
1 year+14.5%——
3-year CAGR+9.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
4.5M USD
Year-over-year change
+14.5%
4-year CAGR
+13.0%

Depreciation & Amortization vs competitors

How LNSR compares with its peers on the latest reported figures

  • LNSR's LTM Mar 2026 depreciation & amortization of $4.56M is the 3rd largest of the 10 companies compared; the peer median is $1.17M.
  • Its year-over-year change of +11.6% is the 2nd highest of 10, against a peer median of -20.5%.
  • Depreciation & amortization amounts to 7.9% of revenue for LNSR, versus a peer median of 6.9%.
LNSR Competitors Peer median
Depreciation & Amortization for LNSR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANIKAnika Therapeutics, Inc.LTM Mar 2026$5.54M -27.5%-26.6%4.8%
MXCTMaxCyte, Inc.LTM Mar 2026$4.68M +4.5%+24.0%14.5%
LNSRLENSAR, Inc.LTM Mar 2026$4.56M +11.6%+9.7%7.9%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$3.11M -8.6%+4.7%9.0%
AVRAnteris Technologies Global Corp.LTM Mar 2026$1.69M +7.8%+29.0%91.1%
CRDFCardiff Oncology, Inc.LTM Mar 2026$1.17M +120.2%+56.5%222.3%
OWLTOwlet, Inc.LTM Mar 2026$627K -41.1%-39.6%0.6%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$589K -20.5%+16.3%1.3%
PROFProfound Medical Corp.LTM Mar 2026$499.37K -27.3%-29.2%2.6%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$287K -146.9%——
Peer median (excluding LNSR) $1.17M-20.5%+10.5%6.9%

Competitors are the stored peer set for LNSR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(19.6M)(19.91M)(14.38M)(31.4M)(34.28M)
Depreciation & Amortization2.76M3.41M3.52M3.93M4.5M
Deferred Income Tax527K0000
Stock-Based Compensation6.87M6.61M5.54M2.67M3.14M
Change in Working Capital(42K)(5.58M)(7.78M)(3.04M)1.1M
Accounts Receivables(2.65M)(1.44M)1.08M(2.1M)289K
Inventory2.33M(6.89M)(7.46M)(4.9M)(13.9M)
Accounts Payables213K2.73M(1.42M)1.96M12.99M
Other Working Capital66K23K23K2M1.72M
Other Non-Cash Items517K618K3.45M25.58M10.7M
Operating Cash Flow(8.97M)(14.86M)(9.66M)(2.28M)(14.83M)
Capital Expenditures(354K)(115K)(236K)(156K)(83K)
Acquisitions (Net)00000
Purchases of Investments00(3.92M)(10.25M)(11.88M)
Sales of Investments0008.24M13.25M
Other Investing Activities00000
Investing Cash Flow(354K)(115K)(4.16M)(2.16M)1.28M
Debt Repayment00000
Common Stock Issued361K408K058K258K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(2.4M)5.88M20K10M
Financing Cash Flow361K(1.99M)19.76M78K10.26M
Effect of Forex Changes00000
Net Change in Cash(8.96M)(16.96M)5.95M(4.36M)(3.29M)
Free Cash Flow(9.32M)(14.97M)(9.9M)(2.43M)(14.91M)

LENSAR, Inc.

NASDAQ:LNSR

Intrinsic Alpha fair value

Locked

Current Price

$4.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.